Viara M, Menicanti V, Nebiolo M, Michos N, Sarchi C
Arzneimittelforschung. 1986 Jul;36(7):1113-5.
In a placebo-controlled double-blind trial analgesic effectiveness and tolerability of alpha-methyl-4-(2-thienyl-carbonyl)phenylacetic acid (suprofen, Suprol) 300 mg suppositories were evaluated for 45 informed patients suffering from chronic pain due to osteoarthritis; the subjects were treated rectally, t.i.d., for 10 days. Suprofen proved to be statistically significantly superior to placebo in all the variables considered for evaluation of the analgesic effect, i.e., pain intensity and relief scores, sum of pain intensity differences (SPID), total pain relief (TOTPAR), global assessments by investigator and patient. In particular, the efficacy of suprofen was judged by the physician good or very good in 86.3% of the patients. Similar frequencies of rectal side-effects were observed in both treatment groups, with slightly but not significantly higher incidence in the group treated with suprofen. Haematologic and clinical chemistry laboratory tests showed no statistically significant alterations due to the treatment.
在一项安慰剂对照双盲试验中，对45名因骨关节炎患有慢性疼痛的知情患者评估了300毫克α-甲基-4-（2-噻吩基羰基）苯乙酸（舒洛芬，Suprol）栓剂的镇痛效果和耐受性；受试者直肠给药，每日三次，共10天。在用于评估镇痛效果的所有变量中，即疼痛强度和缓解评分、疼痛强度差异总和（SPID）、总疼痛缓解（TOTPAR）、研究者和患者的整体评估，舒洛芬在统计学上被证明显著优于安慰剂。特别是，86.3%的患者中医生判断舒洛芬疗效为良好或非常好。两个治疗组观察到相似频率的直肠副作用，舒洛芬治疗组的发生率略高但无显著差异。血液学和临床化学实验室检查显示治疗未引起统计学上的显著改变。
